COMMUNIQUÉS West-GlobeNewswire

-
Genmab to Hold 2024 R&D Update and ASH Data Review Meeting
11/12/2024 -
Two Senior MEDIROM Mother Labs Executives Invest in Mother Labs’ Series A Financing at a Pre-Money Valuation of JPY9 Billion (as of December 1, 2024, approximately USD $59,000,000)
11/12/2024 -
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
10/12/2024 -
Cellectis annonce le tirage de la troisième tranche de 5 millions d’euros dans le cadre du contrat de crédit conclu avec la Banque Européenne d’Investissement (BEI)
10/12/2024 -
Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)
10/12/2024 -
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
10/12/2024 -
Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2024
10/12/2024 -
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member
10/12/2024 -
Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
10/12/2024 -
Interim Results from STOMP Study of SIGA’s Tecovirimat in Treatment of Mpox Announced
10/12/2024 -
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA
10/12/2024 -
Theratechnologies reçoit de la FDA la date cible d’approbation de mars 2025 à la licence de produit biologique mise à jour pour la formulation F8 de la tésamoréline
10/12/2024 -
Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference
10/12/2024 -
UPDATE - Remedy Plan Therapeutics Showcases Preclinical Data from First-In-Class NAMPT Inhibitor, RPT1G, Demonstrating Synergy with BCL-2 Family Inhibitors in AML at the 2024 ASH Annual Meeting
10/12/2024 -
Nutrify Today Introduces a Trio of Innovations to Strengthen NutrifyGenie AI Capabilities
10/12/2024 -
Crossject launches reserved capital increase and warrants issuance for an aggregate amount of at least €7m
10/12/2024 -
Crossject annonce une augmentation de capital et une emission de bons de souscription d’actions reservee à une catégorie d’investisseurs pour un montant total minimum de 7 millions d’euros
10/12/2024 -
CARBIOS announces the initiation of coverage of its stock by STIFEL
10/12/2024 -
CARBIOS annonce l’initiation de couverture de son titre par STIFEL
10/12/2024
Pages